Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF JIANGZHONG PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2023

On 11 April 2023, Jiangzhong Pharmaceutical released its results estimate for the three months ended 31 March 2023.

Jiangzhong Pharmaceutical Co., Ltd.（江中藥業股份有限公司）(“**Jiangzhong Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.06% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd.（華潤江中製藥集團有限責任公司）. The Group controls an effective interest of approximately 22.11% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

On 11 April 2023, Jiangzhong Pharmaceutical released its results estimate for the three months ended 31 March 2023, in which, it announced that the net profit attributable to the shareholders of Jiangzhong Pharmaceutical for the three months ended 31 March 2023 is estimated to be approximately RMB240 million (as compared to the same period last year of approximately RMB183.6972 million), and net profit excluding non-recurring gain or loss is estimated to be approximately RMB224 million (as compared to the same period last year of approximately RMB173.4306 million) (the “**Jiangzhong Pharmaceutical Results Estimate**”).

The main reasons for the change in results is that in the first quarter of 2023, Jiangzhong Pharmaceutical focused on "strengthening OTC, developing big health, and laying out prescription drugs" as its business priority, concentrating on core advantages, and adhering to the development of broad categories and well-known products. Due to the increase in market demand, the Jiangzhong Pharmaceutical's products such as lactic acid bacteria tablets, compound grass coral lozenges and compound fresh bamboo liquid achieved good growth.

Jiangzhong Pharmaceutical Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. The quarterly report for the three months ended 31 March 2023 to be disclosed by Jiangzhong Pharmaceutical shall prevail.

The financial information in this announcement is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational of financial status of the Group. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

For further details of the Jiangzhong Pharmaceutical quarterly financial information, please refer to the quarterly report for the three months ended 31 March 2023 to be published by Jiangzhong Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 12 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.